Morgan Stanley Biocept Inc Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.75 - $1.2 $4 - $7	6 New	6 $0
Q2 2022 Aug 15, 2022	SELL	$0.88 - $2.27 $1,672 - $4,313	-1,900 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$1.83 - $3.97 $3,477 - $7,543	1,900 New	1,900 $4,000
Q1 2022 May 13, 2022	BUY	$1.83 - $3.97 $146 - $317	80 Added 4.4%	1,900 $4,000
Q4 2021 Feb 14, 2022	SELL	$3.43 - $4.22 $24,167 - $29,734	-7,046 Reduced 79.47%	1,820 $6,000
Q3 2021 Nov 15, 2021	BUY	$3.39 - $4.34 $30,055 - $38,478	8,866 New	8,866 $35,000

Ticker BIOC
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,922,900
Market Cap $1.18M
Description
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.